Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas…
Read More...
Read More...
